Investigation Launched into AdaptHealth Corp: Stock Plummets After Earnings Guidance Cut

AdaptHealth Corp. Faces Investigation After Sobering Earnings Guidance Cut

In a startling development for investors, AdaptHealth Corp. (NASDAQ: AHCO) saw its stock price tumble by as much as 26%. This drastic decline occurred after the company announced a significant downward revision to its full-year adjusted EBITDA guidance for 2026. Initially, on May 5, 2026, AdaptHealth projected adjusted EBITDA of between $680 million and $730 million, reassuring investors that elevated labor costs would normalize. However, just weeks later, this outlook was drastically changed, bringing the new forecast down to approximately $490 million to $520 million — a cut of nearly $210 million.

This revision, communicated on August 5, 2026, sent shockwaves through the market, prompting many shareholders to evaluate their options. Investors who purchased shares and have since incurred losses are encouraged to come forward as Levi & Korsinsky, LLP has initiated an investigation into the potential misleading statements made by AdaptHealth.

During the first quarter earnings call, CFO Jason Clemens confidently reassured stakeholders by stating that labor costs were on a downward trajectory and that baseline costs were anticipated to return soon. These comments were made under the backdrop of ongoing efforts to manage expenses related to their capitated arrangement. The CFO had further quantified the expected decline in labor expenses, predicting a normalization of $12 million by the second quarter's end.

Despite these assurances, the subsequent downward adjustment of the EBITDA forecast attributed various operational challenges like the divestiture of its Diabetes Health segment and the impacts of contract pricing strategies. Crucially, management did not forewarn investors that these factors were likely to play a significant role in deteriorating the company’s financial outlook.

This failure to adequately inform investors has raised pertinent questions about transparency and the accuracy of AdaptHealth's guidance. The investigation is expected to scrutinize whether the statements made by small executives constituted material misrepresentations that led to these financially taxing outcomes.

For AHCO investors wishing to take action, gathering brokerage records such as purchase dates, quantities, and transaction prices is the first step. Levi & Korsinsky is actively seeking to evaluate potential claims without upfront costs for the affected shareholders.

Those participating in the investigation can rest assured that no immediate legal action is required, nor will they need to appear in court. The legal process will typically unfold on a contingency basis, meaning if there are no recoveries, there will be no incurred costs at all.

In summary, the situation surrounding AdaptHealth Corp. remains highly dynamic, with significant holes emerging in the narrative presented to investors. As the investigation unfolds, many will watch closely to see the implications for shareholder confidence and the company’s future operations. Those with losses are encouraged to explore their options, as Levi & Korsinsky works to ensure accountability for any wrongdoings.

For any further inquiries or assistance regarding participation in the investigation, concerned parties can reach out to Joseph E. Levi, Esq. at [email protected] or via phone at (212) 363-7500.